NAUT Key Statistics, Chart & Performance
The current stock price of NAUT is 2.07 USD. In the past month the price increased by 53.33%. In the past year, price decreased by -7.59%.
NAUT Latest News, Press Relases and Analysis
NAUT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.16 | 221.31B | ||
| DHR | DANAHER CORP | 29.44 | 162.53B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 181.97 | 55.22B | ||
| A | AGILENT TECHNOLOGIES INC | 28.18 | 43.55B | ||
| IQV | IQVIA HOLDINGS INC | 19.62 | 38.79B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.14 | 30.28B | ||
| WAT | WATERS CORP | 31.46 | 23.78B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.75 | 19.70B | ||
| ILMN | ILLUMINA INC | 28.89 | 19.36B | ||
| MEDP | MEDPACE HOLDINGS INC | 43.25 | 17.42B | ||
| TEM | TEMPUS AI INC | N/A | 13.21B | ||
| RVTY | REVVITY INC | 21 | 11.67B |
Related stock screener links
About NAUT
Company Profile
Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 134 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Company Info
NAUTILUS BIOTECHNOLOGY INC
2701 Eastlake Ave East
Seattle WASHINGTON US
CEO: Adam Stone
Employees: 128
Phone: 12063332001
NAUTILUS BIOTECHNOLOGY INC / NAUT FAQ
What does NAUT do?
Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 134 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Can you provide the latest stock price for NAUTILUS BIOTECHNOLOGY INC?
The current stock price of NAUT is 2.07 USD. The price decreased by -7.59% in the last trading session.
What is the dividend status of NAUTILUS BIOTECHNOLOGY INC?
NAUT does not pay a dividend.
What is the ChartMill technical and fundamental rating of NAUT stock?
NAUT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting NAUT stock to perform?
8 analysts have analysed NAUT and the average price target is 2.55 USD. This implies a price increase of 23.19% is expected in the next year compared to the current price of 2.07.
What is the ownership structure of NAUTILUS BIOTECHNOLOGY INC (NAUT)?
You can find the ownership structure of NAUTILUS BIOTECHNOLOGY INC (NAUT) on the Ownership tab.
NAUT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NAUT. When comparing the yearly performance of all stocks, NAUT is one of the better performing stocks in the market, outperforming 97.2% of all stocks.
NAUT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NAUT. No worries on liquidiy or solvency for NAUT as it has an excellent financial health rating, but there are worries on the profitability.
NAUT Financial Highlights
Over the last trailing twelve months NAUT reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 10.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.26% | ||
| ROE | -37.14% | ||
| Debt/Equity | 0 |
NAUT Forecast & Estimates
8 analysts have analysed NAUT and the average price target is 2.55 USD. This implies a price increase of 23.19% is expected in the next year compared to the current price of 2.07.